Androgen receptor inhibitors in tablet dosage for non-metastatic castration-resistant prostate cancer. Deployed in endocrine oncology practices by specialists. Manufactured under license by pharmaceutical partners, channeled through B2B supply chains to private and public healthcare institutions.